Industri

FDA grants priority review for Roche’s Tecentriq combo ...

The application covers patients with stage III colon cancer characterised by def...

India Pharma 2035: The next global leadership story

Indore Pharma Summit 2026 | 8th May 2026 | Indore Marriott Hotel The post India...

Mr Murali Krishna Veeramallu, Head – Industrial Divisio...

Indore Pharma Summit 2026 | 8th May 2026 | Indore Marriott Hotel The post Mr Mu...

Mr Akil Kadiyavala, GM – Technical Services, Dhara Life...

Indore Pharma Summit 2026 | 8th May 2026 | Indore Marriott Hotel The post Mr Ak...

Mr Ranjit Menon, Site Head – Indore – Manufacturing, Cipla

Indore Pharma Summit 2026 | 8th May 2026 | Indore Marriott Hotel The post Mr Ra...

Mr Vivek Asthana, Head EHS & Sustainability, Symbiotec ...

Indore Pharma Summit 2026 | 8th May 2026 | Indore Marriott Hotel The post Mr Vi...

Panel Discussion: From molecule to market faster: Rethi...

Indore Pharma Summit 2026 | 8th May 2026 | Indore Marriott Hotel The post Panel...

Prof (Dr) Neelesh Malviya, Principal, Smriti College of...

Indore Pharma Summit 2026 | 8th May 2026 | Indore Marriott Hotel The post Prof ...

Indore Rising: Central India’s next manufacturing power...

Indore Pharma Summit 2026 | 8th May 2026 | Indore Marriott Hotel The post Indor...

Mr Gajanan Patil, COO, H&H Healthcare and Cosmetics

Indore Pharma Summit 2026 | 8th May 2026 | Indore Marriott Hotel The post Mr Ga...

Indore Pharma Summit: Mapping the future of India pharma

From AI and smart manufacturing to sustainability,quality culture,faster drug d...

Parexel to present at eight sessions during DIA Global ...

Company representatives to participate in discussions on AI, clinical trials, ...

Planning for Growth: How Healthcare Systems Are Designi...

Healthcare facilities have always been complex to design and build, but today’s ...

XtalPi enters $400m partnership for small molecule ther...

The collaboration follows a successful pilot phase, where XtalPi’s integrated qu...

CDSCO approves Trastuzumab Deruxtecan for first-line HE...

Approval expands indication for Trastuzumab Deruxtecan in combination with Pert...

Glenmark launches Winlevi for acne vulgaris across Euro...

Launch follows European Commission authorisation and expands availability of c...